Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Average (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Equity Average for 12 consecutive years, with $264.7 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 46.57% to $264.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $264.7 million through Dec 2025, up 46.57% year-over-year, with the annual reading at $236.1 million for FY2025, 21.55% up from the prior year.
  • Equity Average for Q4 2025 was $264.7 million at Theravance Biopharma, up from $228.8 million in the prior quarter.
  • The five-year high for Equity Average was $461.2 million in Q4 2022, with the low at -$350.6 million in Q2 2022.
  • Average Equity Average over 5 years is $68.7 million, with a median of $192.5 million recorded in 2024.
  • The sharpest move saw Equity Average plummeted 86.97% in 2021, then surged 302.46% in 2023.
  • Over 5 years, Equity Average stood at -$331.1 million in 2021, then skyrocketed by 239.3% to $461.2 million in 2022, then plummeted by 50.22% to $229.6 million in 2023, then decreased by 21.33% to $180.6 million in 2024, then skyrocketed by 46.57% to $264.7 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $264.7 million, $228.8 million, and $195.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.